Drug Profile
IBPM 004AM
Alternative Names: IBPM004AM; IBPM004AM (biosimilar) - Inbiopro SolutionsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inbiopro Solutions
- Class Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ankylosing-spondylitis in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Juvenile-rheumatoid-arthritis in India (Parenteral)